Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS)‘s stock had its “overweight” rating reissued by analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Aptose Biosciences’ FY2022 earnings at ($0.45) EPS and FY2023 earnings at ($0.42) EPS.
Separately, StockNews.com assumed coverage on Aptose Biosciences in a research note on Monday. They issued a “hold” rating on the stock.
Aptose Biosciences Trading Down 4.9 %
Shares of APTO opened at $0.61 on Wednesday. The company has a market capitalization of $55.83 million, a PE ratio of -0.96 and a beta of 1.48. Aptose Biosciences has a 12 month low of $0.58 and a 12 month high of $2.78. The stock’s 50-day moving average price is $0.78 and its two-hundred day moving average price is $0.96.
Institutional Trading of Aptose Biosciences
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Gleason Group Inc. bought a new stake in Aptose Biosciences in the 1st quarter valued at about $25,000. Sequoia Financial Advisors LLC bought a new stake in Aptose Biosciences in the 1st quarter valued at about $27,000. Rockefeller Capital Management L.P. increased its position in Aptose Biosciences by 1,334.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 21,809 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 20,289 shares in the last quarter. Bayesian Capital Management LP bought a new stake in Aptose Biosciences in the 4th quarter valued at about $51,000. Finally, Toronto Dominion Bank increased its holdings in Aptose Biosciences by 76.6% during the 1st quarter. Toronto Dominion Bank now owns 50,186 shares of the biotechnology company’s stock worth $68,000 after purchasing an additional 21,776 shares in the last quarter. 27.16% of the stock is owned by institutional investors.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
- Get a free copy of the StockNews.com research report on Aptose Biosciences (APTO)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.